Symbia Pro.Specta Q3
Payments companies reported to CMS as associated with Symbia Pro.Specta Q3. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Symbia Pro.Specta Q3, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Symbia Pro.Specta Q3
These are the largest totals companies reported as associated with Symbia Pro.Specta Q3. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Elcin Zan | New York, NY | Nuclear Imaging & Therapy | $1,427.35 |
| Peter Liu | Cleveland, OH | Diagnostic Radiology | $1,318.39 |
| Nicholas Austin | Cleveland, OH | Diagnostic Radiology | $1,127.13 |
| Frankis Almaguel | San Bernardino, CA | $78.36 | |
| Christopher Carroll | Boston, MA | Physician Assistant | $39.77 |
| Margaret White-Guthro | Newburyport, MA | Nurse Practitioner | $39.77 |
| Umar Mahmood | Boston, MA | Diagnostic Radiology | $39.77 |
| Shadi Abdar Esfahani | Framingham, MA | Diagnostic Radiology | $39.77 |
| Bashar Kako | Boston, MA | Diagnostic Radiology | $39.77 |
| Sheung Chee Ng | Boston, MA | Diagnostic Radiology | $39.77 |
Prescribed Symbia Pro.Specta Q3?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.